Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sutent maintenance in advanced urothelial carcinoma
NCT00393796Phase 2Terminated
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- May 2006
- Primary completion
- Dec 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in urothelial carcinoma (UC) comparing SUTENT Arm with Placebo Arm (2 arms). Primary endpoint: Percentage of Participants That Experience Progression by 6 Months. Started May 2006; status: terminated.
02
Drugs
sunitinib
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT00393796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00393796.